CLOs on the Move

Redpin Therapeutics

www.redpinrx.com

 
Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.redpinrx.com
  • 101 Sixth Avenue Third Floor
    New York, NY USA 10013
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Iomai Corporation

Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Landmark Bio

Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.

Eastern Isotopes

Eastern Isotopes is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Augustine Biomedical Design

Augustine Biomedical Design is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.